# Phase 2 Leukemia, Myeloid, Acute trials: 173 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 173 trials in phase 2 for Leukemia, Myeloid, Acute that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Leukemia, Myeloid, Acute trials: 173 rows for $8.65, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/leukemia-myeloid-acute

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 173
- Recruiting or not yet: 173
- Read on: November 19, 2026

## Trials

The 25 newest of 173, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07937124 | An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC) | First Affiliated Hospital of Zhejiang University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937124) |
| November 9, 2026 | NCT07925554 | Interferon-α Maintenance in Favorable-Risk AML | Peking University People's Hospital | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925554) |
| October 15, 2026 | NCT07874737 | Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia | The Affiliated People's Hospital of Ningbo University | Phase 2 | Not yet recruiting | Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874737) |
| October 9, 2026 | NCT07867626 | Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML | Rutgers, The State University of New Jersey | Phase 2 | Not yet recruiting | Acute Myeloid Leukaemia (AML) | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867626) |
| October 7, 2026 | NCT07862517 | Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of... | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862517) |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| August 24, 2026 | NCT07783100 | Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Relapsed or Refractory Acute Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783100) |
| August 10, 2026 | NCT07755202 | Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, AML With FLT3 Mutation | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755202) |
| August 10, 2026 | NCT07754799 | A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754799) |
| August 5, 2026 | NCT07748455 | HMA-Venetoclax Induction in Newly Diagnosed AML | Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 2 | Not yet recruiting | AML, AML (Acute Myeloid Leukemia) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748455) |
| August 3, 2026 | NCT07743112 | A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia | Maxinovel Pty., Ltd. | Phase 2 | Recruiting | Acute Myeloid Leukemia | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743112) |
| July 29, 2026 | NCT07735208 | Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia | University of Rochester | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735208) |
| July 17, 2026 | NCT07710534 | Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN | Virginia Commonwealth University | Phase 2 | Recruiting | Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710534) |
| July 7, 2026 | NCT07686107 | Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." | Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | Not yet recruiting | Leukemia, Myeloid, Acute | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686107) |
| June 26, 2026 | NCT07672262 | VA Consolidation in Intermediate-Risk AML | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672262) |
| June 24, 2026 | NCT07664839 | Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation, IDH2 Mutation | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664839) |
| June 11, 2026 | NCT07643636 | Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML | Dongguan People's Hospital | Phase 2 | Not yet recruiting | AML (Acute Myeloid Leukemia) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643636) |
| June 11, 2026 | NCT07642453 | VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | Hematology department of the 920th hospital | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642453) |
| June 9, 2026 | NCT07634536 | Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant | Stanford University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634536) |
| June 3, 2026 | NCT07623616 | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | Kyowa Kirin Co., Ltd. | Phase 2 | Recruiting | Acute Myeloid Leukemia (AML) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623616) |
| May 26, 2026 | NCT07607418 | Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS | Ruijin Hospital | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607418) |
| May 26, 2026 | NCT07605949 | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Leukemia Acute Myeloid | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07605949) |
| May 20, 2026 | NCT07598110 | FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION... | Institut Paoli-Calmettes | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598110) |
| May 12, 2026 | NCT07582172 | Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582172) |
| May 8, 2026 | NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell, Conditioning Therapy, SHR2554... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575412) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 10 |
| National Cancer Institute (NCI) | 10 |
| The First Affiliated Hospital of Soochow University | 9 |
| First Affiliated Hospital of Zhejiang University | 6 |
| Ruijin Hospital | 6 |
| Institute of Hematology & Blood Diseases Hospital, China | 6 |
| Fred Hutchinson Cancer Center | 5 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Masonic Cancer Center, University of Minnesota | 4 |
| Beijing 302 Hospital | 4 |
| City of Hope Medical Center | 4 |
| The First Affiliated Hospital of Xiamen University | 4 |
| Peking University People's Hospital | 3 |
| Technische Universität Dresden | 3 |
| Navy General Hospital, Beijing | 2 |
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2 |
| Chinese PLA General Hospital | 2 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2 |
| University of Rochester | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| Children's Hospital of Soochow University | 2 |
| Center for International Blood and Marrow Transplant Research | 2 |
| University of Washington | 2 |
| University of Manitoba | 2 |
| Institut Paoli-Calmettes | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 70 |
| China | 51 |
| Canada | 8 |
| France | 7 |
| Puerto Rico | 6 |
| Germany | 5 |
| Italy | 4 |
| Spain | 3 |
| United Kingdom | 3 |
| Brazil | 3 |
| Russia | 3 |
| Australia | 2 |
| Netherlands | 2 |
| Norway | 2 |
| Poland | 2 |
| Sweden | 2 |
| Denmark | 2 |
| Japan | 1 |
| Hong Kong | 1 |
| Austria | 1 |
| Belgium | 1 |
| Switzerland | 1 |
| South Korea | 1 |
| Egypt | 1 |
| Pakistan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Vietnamese restaurants in the United States](https://specstream.ai/data/businesses/vietnamese-restaurants/united-states)
- [Electrical wholesalers in the United States](https://specstream.ai/data/businesses/electrical-wholesalers/united-states)
- [Paralegal companies in the United States](https://specstream.ai/data/businesses/paralegal-companies/united-states)
- [Architectural design firms in the United States](https://specstream.ai/data/businesses/architectural-design-firms/united-states)
- [Forklift dealers in the United States](https://specstream.ai/data/businesses/forklift-dealers/united-states)
- [Public adjusters in the United States](https://specstream.ai/data/businesses/public-adjusters/united-states)
